Skip to content

Ananda Developments - First Cannabinoid Medicines Launched

Announcement provided by

Ananda Developments Plc · ANA

27/07/2023 07:00

Ananda Developments - First Cannabinoid Medicines Launched
RNS Number : 3310H
Ananda Developments PLC
27 July 2023

27 July 2023



("Ananda" or the "Company")


First cannabinoid medicines launched


Ananda's ambition is to be a leading provider of high-quality cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions. 



•     Ananda's wholly owned subsidiary MRX Medical Limited (MRX) has today launched its first two cannabinoid medicines MRX1 and MRX2 on to the unlicenced medicinal products (specials) market

•     The oils will be listed on the formularies (list of prescribable medicines) of three private pain and medical cannabis prescribing clinics in the UK

•     MRX1 has been selected to be used in the two Phase II, double blind, RCTs (Randomised Control Trials) run by researchers at the university of Edinburgh


Ananda's CEO, Melissa Sturgess, commented: "We are determined to win NHS support for our cannabinoid medicines with our rigorous approach to formulation development, clinical trials and traditional pharmaceutical data collection. We believe that MRX is in the strongest position to do exactly that.  With NHS endorsement we can bring these medicines to the millions of people who need them and deliver revenues to Ananda." 


Following the signing of the final manufacturing agreement with MRX's contract manufacturing organisation (CMO) on 26 July 2023 after market close, Ananda is pleased to announce that as of today both MRX1 and MRX2 are now available for Specialist doctors to prescribe to their patients.


Both MRX1 and MRX2, as well as a to-be released formulation MRX3 are patent pending. There is a fourth pending patent application which covers MRX's proprietary method for formulating these medicines. MRX1 is also to be used in two Investigative Medicinal Products (IMPs), which will be used in two Phase II RCTs. The RCTs are investigating the efficacy of cannabidiol in treating chemotherapy induced peripheral neuropathy (CIPN) and endometriosis. Both trials are being conducted by world leading clinician investigators at the University of Edinburgh and collectively have received commitments for £1.55m of non-dilutive grant funding.


For all prescriber and clinic enquiries related to MRX medicines please contact Jack Morgan at Please also visit the MRX website,





The Directors of the Company accept responsibility for the contents of this announcement.



+44 (0)7463 686 497

Chief Executive Officer

Melissa Sturgess

Finance Director

Jeremy Sturgess-Smith


+44 (0)20 3470 0470

Corporate Finance

Richard Morrison

Harry Davies-Ball


Corporate Broking

Abigail Wayne

Rob Rees



About Ananda Developments


Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.


To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:


•              Instagram:  

•              LinkedIn:  

•              Twitter:  


For more information, please visit:


Market Abuse Regulation (MAR) Disclosure


The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

ANA announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal